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Diseases Clinical Research Program)A B S T R A C TObjectives: To assess the reliability, validity, and responsiveness of
InFLUenza Patient-Reported Outcome (FLU-PRO©) scores for quantifying
the presence and severity of influenza symptoms. Methods: An observa-
tional prospective cohort study of adults (Z18 years) with influenza-like
illness in the United States, the United Kingdom, Mexico, and South
America was conducted. Participants completed the 37-item draft
FLU-PRO daily for up to 14 days. Item-level and factor analyses were
used to remove items and determine factor structure. Reliability of
the final tool was estimated using Cronbach α and intraclass
correlation coefficients (2-day reliability). Convergent and known-
groups validity and responsiveness were assessed using global
assessments of influenza severity and return to usual health.
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1016/j.jval.2017.04.014comprised the analytical sample. The mean age of the patients was 40.7
years, 60.2% were women, and 59.7% were white. The final 32-item
measure has six factors/domains (nose, throat, eyes, chest/respiratory,
gastrointestinal, and body/systemic), with a higher order factor repre-
senting symptom severity overall (comparative fit index ¼ 0.92; root
mean square error of approximation ¼ 0.06). Cronbach αwas high (total ¼
0.92; domain range ¼ 0.71–0.87); test-retest reliability (intraclass
correlation coefficient, day 1–day 2) was 0.83 for total scores and 0.57
to 0.79 for domains. Day 1 FLU-PRO domain and total scores were
moderately to highly correlated (Z0.30) with Patient Global Rating of
Flu Severity (except nose and throat). Consistent with known-groups
validity, scores differentiated severity groups on the basis of global
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Subjects reporting return to usual health showed significantly greater
(P o 0.05) FLU-PRO score improvement by day 7 than did those who
did not, suggesting score responsiveness. Conclusions: Results sug-
gest that FLU-PRO scores are reliable, valid, and responsive to change
in influenza-positive adults.Keywords: influenza, patient-reported outcome, psychometric, 
reliability, responsiveness, validity.Introduction
Approximately 5% to 20% of the US population is infected with
influenza yearly, with 200,000 hospitalizations and 36,000 deaths
[1–3]. Worldwide, influenza causes 3million to 5million severe cases
and 250,000 to 500,000 deaths annually [4]. Symptoms range from
mild to severe and include various systemic and respiratory symp-
toms, with gastrointestinal symptoms occurring less frequently [3].
Despite the prevalence of influenza and many research
studies evaluating its natural history and treatment options,
there are few validated patient-reported outcome measures for
quantifying symptoms. Two previously developed instruments
have been published but are limited by the populations studied
with smaller numbers of patients with influenza studied com-
pared with influenza-like illness (ILI) [5,6].
A validated, standardized patient-reported influenza symptom
scale that comprehensively assesses the symptom experience in
influenza across multiple body systems would allow for consistent,
accurate assessments of symptoms associated with various viral
strains over the course of the disease within and across subgroups.
Use would facilitate meta-analyses, cross-product evaluations, and
more precise estimates of treatment effects. Standardized measures
should be developed using good research practices [7–9]. Instruments
intended for use in drug development should address recommen-
dations of the US Food and Drug Administration [10], including
attention to content validity and quantitative testing in the target
population for designated contexts of use.
The purpose of the InFLUenza Patient-Reported Outcome (FLU-
PRO©) measure is to comprehensively assess the presence and
severity of influenza symptoms across body systems often affected
by these viruses. The ultimate intent was to develop a reliable,
valid, and responsive measure for use in profiling the symptomatic
manifestations of influenza on any given day, track changes over
time, and test the effects of treatments. To ensure content validity,
we used a two-stage qualitative instrument development method-
ology. In stage 1, we conducted concept elicitation interviews in the
United States and Mexico to gather information regarding patient
experience of influenza symptoms (i.e., type, magnitude, expres-
sion, pattern of onset, and recovery) [11,12]. Results informed the
development of a draft measure, including content (candidate
items), structure (response options, recall, and instructions), and
conceptual framework [13]. In stage 2, we conducted cognitive
interviews to assess completeness, comprehension, and ease of
use of the draft measure from the respondent’s perspective [13].
This work resulted in a draft instrument with 37 candidate
questions ready for quantitative testing in the target population.
The objectives of this study were to 1) evaluate performance
of the 37 candidate items; 2) reduce the number of items as
empirically and conceptually appropriate; 3) finalize measure-
ment/domain structure and develop a scoring algorithm for the
final instrument, the FLU-PRO; and 4) explore the reliability,
validity, and responsiveness of FLU-PRO total and domain scores.
Methods
Study Design and Sample
This was a prospective, observational study of English- and
Spanish-speaking hospitalized and nonhospitalized adults 18 yearsor older with acute influenza. Patients seeking care for influenza
symptoms at participating military or civilian clinics in the United
States (16 sites), Argentina (2 sites), the United Kingdom (1 site),
and Mexico (3 sites) were recruited in influenza seasons in north-
ern and southern hemispheres. Influenza status was assessed
through a positive polymerase chain reaction, rapid antigen test,
and/or viral culture by nasal or nasopharyngeal swab.
We prespecified subjects testing positive for influenza as the
target population and the primary analytical sample, with a goal
of 200 or more subjects (100 for confirmatory factor analysis [CFA]
and 185 [5 per item] for exploratory factor analysis [EFA]) [14],
assuming that 50% of enrolled subjects testing positive for
influenza would permit separate analyses on performance of
the FLU-PRO in ILI. Given the different context of use, ILI results
are presented elsewhere.
A total of 536 English- and Spanish-speaking patients were
enrolled in the study; 441 had diary entries on day 1 and at least 1
day thereafter, qualifying them for analyses. Two hundred
twenty-one were influenza-positive (see Appendix Figure S2 in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2017.04.014).Procedures
Clinical research coordinators recruited participants with
influenza-like symptoms. Patients providing consent: 1) com-
pleted clinic-based baseline assessments of sociodemographic
and clinical characteristics; 2) were tested for laboratory-
confirmed influenza; and 3) completed daily diaries for up to
14 days after enrollment. This included the 37-item draft
FLU-PRO symptom diary and nine additional questions for
validation purposes. At Mexico sites, diaries were completed via
telephone interviews with data entered directly into a Web-based
portal. Participants in the United States, the United Kingdom, and
Argentina completed the survey via either an interviewer-
administered method or a Web-based system using their per-
sonal devices. Translation procedures for Spanish followed the
International Society for Pharmacoeconomics and Outcomes
Research guidelines [15]. The study was conducted with informed
consent, institutional review board approval, and in accordance
with the Declaration of Helsinki [15].Instruments: Patient-Reported Outcomes
InFLUenza Patient-Reported Outcome
The draft FLU-PRO Questionnaire instructed respondents to rate
the severity of 37 influenza symptoms over the past 24 hours,
including those related to the nose, throat, eye, chest, head,
stomach, fatigue, and body aches/pains. Six items measured the
same symptom using different wording to select the best
performing item for the final instrument. For 32 of the 37 items,
respondents rated the severity of each symptom on five-point
Likert-type scales, with 0 indicating “Not at all”; 1, “A little bit”; 2,
“Somewhat”; 3, “Quite a bit”; and 4, “Very much.” For the five
remaining items, severity is expressed as frequency of occur-
rence: vomiting or diarrhea (0 time, 1 time, 2 times, 3 times, or
4 or more times). Sneezing, coughing, and coughed-up mucus
or phlegm were expressed on a scale from 0 (“Never”) to
4 (“Always”), with higher scores indicating more severe
symptoms.
Patient Global Rating of Flu Severity
The Patient Global Rating of Flu Severity assesses patients’
perceptions of overall influenza symptom severity scored as 0
(“No flu symptoms today”), 1 (“Mild”), 2 (“Moderate”), 3 (“Severe”),
and 4 (“Very severe”).
Patient Global Assessment of Interference in Daily Activities
The Patient Global Assessment of Interference in Daily Activities
assesses interference in daily activities because of influenza
symptoms scored as 1 (“Not at all”), 2 (“A little bit”), 3 (“Some-
what”), 4 (“Quite a bit”), and 5 (“Very much”).
Patient Global Assessment of Physical Health
The Patient Global Assessment of Physical Health assesses
general physical health scored as 1 (“Poor”), 2 (“Fair”), 3 (“Good”),
4 (“Very good), and 5 (“Excellent”).
Return to “usual” health and activities
Patients were asked to respond (yes/no) to the questions “Have
you returned to your usual activities today?” and “Have you
returned to your usual health today?”
Statistical Analyses
Analyses were based on the classical test theory [16] performed
on the influenza-positive cohort with at least 2 days of FLU-PRO
data: day 1 and at least 1 day thereafter. Analyses were con-
ducted in two phases:
Phase I: Finalize the instrument and scoring algorithm,
including item-level descriptive statistics, item-to-item cor-
relations, CFA, and EFA [17].
Phase II: Evaluate the psychometric properties of FLU-PRO
scores, including reliability, validity, and responsiveness.Phase I: Finalize the instrument and scoring algorithm
Item analysis. Day 1 data were used to examine distributional
characteristics of the items, including mean, median, range,
mode, percentages of minimum and maximum responses for
floor and ceiling effects, percentage missing, and the frequency
and percentage of each response category. Items were flagged for
further consideration if they showed floor effects (minimum
response 425%) or ceiling effects (maximum response 425%).
Spearman correlations were used to calculate interitem correla-
tions among items.
Confirmatory factor analysis. CFA was used to assess the fit of
the hypothesized three-domain structure (see Appendix Figure S1
in Supplemental Materials found at http://dx.doi.org/10.1016/j.
jval.2017.04.014): upper respiratory (nose, throat, and eye symp-
toms), lower respiratory (chest symptoms), and systemic (head,
gastrointestinal, sleep, and body/systemic symptoms). The model
was tested using a weighted least squares mean and variance-
adjusted estimator, with fit assessed using the comparative fit
index (CFI), root mean square error of approximation (RMSEA),
and weighted root mean square residual (WRMR). CFI greater
than 0.90, RMSEA less than 0.07, and WRMR close to 1 [18,19] were
considered acceptable. Items with standardized coefficient less
than 0.30 were reviewed for possible deletion.Exploratory factor analysis. EFA was prespecified for follow-up
analysis if there was a misfit of the hypothesized model. This EFA
accounted for the ordinal categorical nature of the variables, with
no prespecified number of factors. Values for CFI, standardized
root mean square residual, and RMSEA were examined to assess
model goodness of fit. Acceptable model fit was indicated when
values of root mean square residual were less than 0.08 [20] and
RMSEA were less than 0.07 [18,19]. Approximation of simple
structure with factor loadings of 0.4 or higher was the criterion
for accepting a factor solution; oblique rotation was used. CFA
and EFA were conducted using Mplus software (Muthén &
Muthén, Los Angeles, CA) [21].
Phase II: Evaluate psychometric properties
Reliability (internal and test-retest). Cronbach formula for coef-
ficient α was used to estimate internal consistency reliability of
the FLU-PRO total and domain scores as appropriate at day 1.
Coefficients of 0.7 to 0.9 were prespecified as “good” internal
consistency, 0.4 to less than 0.7 as “moderate,” and less than 0.4
as “low” or “poor” [16,22].
Test-retest reliability was estimated using data from patients
reporting “no change” on the Patient Global Rating of Change in
Flu Severity on two consecutive days from week 1 (day 1–day 7).
Intraclass correlation coefficients (ICCs; fixed-effects model),
paired t tests, and effect size (ES) were examined. ICCs were
expected to be higher than 0.60 and mean differences insignif-
icant with small ES (o0.20).
Construct validity. Construct validity is the degree to which scores
from one measure are related to those of other measures in a
manner consistent with theory. Relationships between FLU-PRO
scores and the three global ratings were assessed using Spear-
man correlations (r), day 1 and day 3, with the expectation that
the strongest relationship would be with the patient rating of flu
severity, followed by physical health and interference in daily
activities, with all coefficients moderate to high (40.30) [23].
Known-groups validity. Known-groups validity tests score dif-
ferences between two or more groups known to differ on the
underlying construct [24]. In this study, analysis of variance was
used to compare FLU-PRO scores across day 1 in Patient Global
Rating of Flu Severity categories: “None” or “Mild,” “Moderate,”
and “Severe” or “Very severe.” Scheffe test was used for pairwise
comparisons.
Hospitalization status was not used to test known-groups
validity. Patients can be admitted to the hospital at any time
during an influenza episode. Dates of influenza symptom onset,
hospital admission, and discharge were not gathered during the
study, precluding “day 1 to day 1” between-group comparisons.
Patients with influenza are hospitalized for various reasons,
including worsening of underlying conditions [25–27]. Because
data on comorbid conditions or admitting diagnoses were not
available, these factors could not be controlled. Finally, the extent
to which influenza symptoms are actually worse in hospitalized
versus outpatients has not been shown. Therefore, although the
two groups are “known,” the nature of differences (if any) on
underlying constructs is not precluding their use as validity
indicators.
Responsiveness. To test responsiveness [28], analysis of cova-
riance compared changes in FLU-PRO scores at day 7 in respond-
ers (returned to usual health/activity) and nonresponders (not
returned to usual health/activity), adjusting for day 1 scores,
expecting that responders would have significantly larger (P o
0.05) change scores.
Table 1 – Subjects’ demographic and clinical char-









Mean  SD 39.4  16.1 43.5  17.5
Median (range) 36.0 (18–86) 41.0 (18–95)
465 years
Sex: female, n (%) 92 (61.3) 41 (57.7)
Ethnicity, n (%)†
Hispanic or Latino 16 (10.7) 67 (94.4)
Non-Hispanic or Latino 133 (88.7) 4 (5.6)
Race, n (%)
American Indian or Alaska
Native
4 (2.7) 0
Asian 5 (3.3) 0
African American 74 (49.3) 0
Mestizo 0 (0) 67 (94.4)
White 61 (40.7) 4 (5.6)
Other 6 (4.0) 0
Employment status, n (%)
Employed, full-time or
part-time
81 (54.0) 33 (46.5)
Retired 11 (7.3) 3 (4.2)
Other‡ 36 (24.0) 31 (43.7)
Missing 22 (14.7) 4 (5.6)
Military status, n (%)
Never in the military 61 (40.7) 67 (94.4)
Active 40 (26.7) 0
Retired 10 (6.7) 0
Other§ 16 (10.6) 0
Missing 23 (15.3) 4 (5.6)
Highest level of education, n (%)
Secondary/high school or less 43 (28.7) 29 (40.8)
Some college 33 (22.0) 4 (5.6)
College degree or more 42 (28.0) 31 (43.7)
Other 32 (21.3) 7 (9.9)
Current treatments, n (%)
Oseltamivir (Tamiflu) 50 (33.3) 13 (18.3)
Amantadine (Symmetrel) 0 (0.0) 2 (2.8)
Other 56 (37.3) 42 (59.2)
None 57 (38.0) 19 (26.8)
Comorbidities||, n (%)
None 56 (37.3) 29 (40.8)
Asthma 38 (25.3) 11 (15.5)
Chronic obstructive
pulmonary disease
9 (6.0) 0 (0.0)
Osteoporosis 1 (0.7) 1 (1.4)
Depression 17 (11.3) 4 (5.6)
Hypertension 20 (13.3) 13 (18.3)
Raised cholesterol 12 (8.0) 10 (14.1)
Stomach ulcers 3 (2.0) 3 (4.2)
Heart attack/angina 2 (1.3) 1 (1.4)
Diabetes 22 (14.7) 8 (11.3)
Kidney disease 6 (4.0) 2 (2.8)
Lung disease 3 (2.0) 2 (2.8)
Tuberculosis 0 (0.0) 2 (2.8)
Other 39 (26.0) 17 (23.9)
* Other countries include Mexico (n ¼ 67), Argentina (n ¼ 3), and
the United Kingdom (n ¼ 1).
† One participant had missing ethnicity.
‡ Other includes homemaker, student, unemployed, and others.
§ Other includes reserves and others.
|| Not mutually exclusive.Results
Table 1 and S2 presents sample baseline demographic and
clinical characteristics.
Phase I: Item Evaluation, Item Reduction, and Domain
Structure
Item analysis
The full range of response options was used for all 37 candidate
items; 25 items (68%) were flagged for further evaluation because
of floor effects. No item reached the ceiling threshold of 25% (see
Appendix Table S1 in Supplemental Materials found at http://dx.
doi.org/10.1016/j.jval.2017.04.014).
No interitem correlation coefficient was higher than 0.80,
suggesting no redundancy (data not shown). The strongest
correlations (rs 4 0.60) occurred across pairs of related items
within systems, for example, chills, shivering, and felt cold (0.73);
swollen throat and difficulty swallowing (0.64); chest tightness
and trouble breathing (0.62); and chest congestion (0.67). The
weakest correlations (rs o 0.05) were between items assessing
different body systems or logical inconsistencies, such as teary,
watery eyes with wet/loose cough (0.04) and coughing mucus
(0.01), or diarrhea frequency with sore or painful throat (0.00) or
difficulty swallowing (0.01) (see Table S2 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2017.04.014).
Confirmatory factor analysis
The hypothesized three-factor model with upper respiratory,
lower respiratory, and systemic symptoms demonstrated unac-
ceptable global fit (CFI ¼ 0.836; RMSEA ¼ 0.089; WRMR ¼ 1.722).
Modification indices suggested a model with several items load-
ing on more than one factor. Because the statistically optimized
model would have been difficult to interpret, EFAs were per-
formed to examine a simpler structure more consistent with
qualitative data and clinical evaluations of influenza symptoms
across multiple body systems.
EFA and item reduction
EFA models with 4 to 15 factors showed acceptable fit indices.
A seven-factor solution best approximated the hypothesized
conceptual framework, was clinically interpretable, and achieved
the best fit (see Appendix Table S3 in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2017.04.014). This model
included domains assessing nose, throat, eyes, chest, head/body,
gastrointestinal, and sleep.
Individual items were discussed by the study team, examining
item and factor-level performance, insight from patients from the
qualitative research, and clinical considerations. Two sleep items
were removed (“Difficulty staying asleep” and “Difficulty falling
asleep”). “Sleeping more than usual” was retained as the best
question to represent sleep disturbance associated with systemic
manifestations of influenza.
Revised conceptual framework and scoring
The final conceptual framework for the FLU-PRO (Fig. 1) is a six-
factor structure (nose [4 items], throat [3 items], eyes [3 items],
chest/respiratory [7 items], gastrointestinal [4 items], and
body/systemic [11 items]), with a higher order factor represent-
ing influenza symptom severity (CFI ¼ 0.92; RMSEA ¼ 0.06;
WRMR ¼ 1.23).
A mean-based scoring algorithm was selected, with total scores
calculated by computing means across all 32 items. This yields
weighted total scores, dominated by chest/respiratory (22%) and
body/systemic (34%) symptoms. To ensure representation of all
body systems in the overall score, total scores are computed only
if there are sufficient data to compute each domain score.
Scores range from 0 to 4; higher scores indicate more severe
symptoms.Phase II: Evaluation of Psychometric Properties
Overall results for influenza-positive patients are reported herein;
results stratified by hospitalization status are provided in
Supplemental Materials Tables S6 through S11 and Figure S3
found at http://dx.doi.org/10.1016/j.jval.2017.04.014.
The analytical sample included influenza-positive partici-
pants with FLU-PRO diary data on day 1 and at least 1 day
thereafter. Missing data increased over time with variance
observed by geographic region. Specifically, 53% of US patients
completed diaries on days 1, 2, and 3, compared with 89% outside
the United States. By day 7, completion rates were 28% and 82%
for US and ex-US subjects, respectively. Further analyses showed
high rates of compliance during active influenza symptom
days, with 90% of subjects completing the diary to symptom
resolution, defined by return to usual health or activity. There-
fore, most missing data were not informative regarding symptom
course.Descriptive statistics of FLU-PRO total and domain scores
Distributional characteristics of day 1 FLU-PRO scores are pre-
sented in Table 2. Figure 2 displays mean FLU-PRO scores over
time.Fig. 1 – Final FLU-PRO conceptual framework. FLUReliability (internal and test-retest)
Cronbach α was high for all domains (nose ¼ 0.81, throat ¼ 0.81,
eyes ¼ 0.81, chest/respiratory ¼ 0.80, gastrointestinal ¼ 0.71,
body/systemic ¼ 0.87) and the total score (0.92).
For test-retest reliability, day 1 to day 2 (n ¼ 44), score
reliability values for eyes (ICC ¼ 0.62), chest/respiratory (ICC ¼
0.76), gastrointestinal (ICC ¼ 0.62), and body/systemic (ICC ¼ 0.65)
domains were considered acceptable according to the ES and ICC
estimates, whereas the nose values (ICC ¼ 0.79) and total score
(ICC ¼ 0.83) were acceptable according to the ICC estimate (the
throat values did not meet thresholds; ICC ¼ 0.57). All other 2-day
assessment points, FLU-PRO ES, and ICC estimates were
acceptable (except for body/systemic at day 2–day 3 and day 6–
day 7) (see Appendix Table S4 in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2017.04.014).
Construct Validity
As hypothesized, at day 1 the strongest association was between
the FLU-PRO total scores and the Patient Global Rating of Flu
Severity (r ¼ 0.59; P o 0.0001), followed by Interference in Daily
Activities (r ¼ 0.43; P o 0.0001) and Physical Health (r ¼ 0.29; P o
0.0001) (see Appendix Table S5 in Supplemental Materials found
at http://dx.doi.org/10.1016/j.jval.2017.04.014). Domain scores dis-
played moderate to large associations with patient ratings of Flu
Severity (r ¼ 0.34–0.61) except for nose (r ¼ 0.27) and throat (r ¼
0.28), with all coefficients statistically significant (P o 0.0001).
There was a moderate to large correlation between the body/
systemic domain and more distal ratings of Interference in Daily
Activities (r ¼ 0.50; P o 0.0001); correlations between this
global rating and other FLU-PRO domains were smaller (r ¼ 0.11-PRO, inFLUenza Patient-Reported Outcome.
Table 2 – 32-Item FLU-PRO domain and total score descriptive statistics (N ¼ 221), day 1.
Scale Mean  SD Range, median (mode) Floor effect, n (%) Ceiling effect, n (%)
Nose 1.7  1.1 0.0–4.0, 1.5 (1.3) 13 (5.9) 4 (1.8)
Throat 1.4  1.1 0.0–4.0, 1.0 (0.0) 41 (18.6) 5 (2.3)
Eyes 1.0  1.1 0.0–4.0, 0.7 (0.0) 67 (30.3) 8 (3.6)
Chest/respiratory 1.9  0.9 0.0–4.0, 1.9 (1.7) 3 (1.4) 2 (0.9)
Gastrointestinal 0.7  0.8 0.0–3.8, 0.3 (0.0) 77 (34.8) 0 (0.0)
Body/systemic 1.8  0.9 0.0–3.8, 1.8 (2.5) 2 (0.9) 0 (0.0)
Total score 1.6  0.7 0.3–3.7, 1.6 (1.3) 0 (0.0) 0 (0.0)
Notes. Higher FLU-PRO scores ¼ more severe symptoms.
FLU-PRO, inFLUenza Patient-Reported Outcome.[nonsignificant] to 0.29 [P o 0.0001]). Similarly, there were weaker
associations between domain scores and patients’ ratings of
Physical Health (r ¼ 0.06 [nonsignificant] to 0.28 [P o 0.0001]).
Known-Groups Validity
Significant differences in FLU-PRO scores were observed across
the known global Flu Severity rating groups (F ¼ 57.2; P o 0.001).
Mean scores were the lowest in the No/Mild symptoms group
(0.98  0.47), followed by the Moderate (1.38  0.57) and Severe/
very severe (2.01  0.63) groups, with all pairwise comparisons
statistically significant (P o 0.001). For domain scores, mean
values for the No/mild symptoms group were the lowest (mean
range ¼ 0.29–1.37), followed by the Moderate (mean range ¼ 0.48–
1.75) and Severe/very severe (mean range ¼ 1.06–2.48) groups.
Pairwise comparisons showed similar patterns to the total score
except for the No/mild symptoms group versus the Moderate
group for nose, throat, eyes, and gastrointestinal domains, which
were in the correct direction but nonsignificant (P 4 0.05)
(Table 3). This may be due to smaller numbers of patients
experiencing these symptoms, reducing variability.Fig. 2 – FLU-PRO domain and total score by diary day 1–dResponsiveness
Mean total and domain change scores were significantly greater
for patients reporting return to usual health (responders) by day 7
compared with those who did not, except for the gastrointestinal
domain (Table 4). Mean change scores were significantly greater
for patients reporting return to usual activities (responders) by
day 7 compared with those who did not, except for the eyes
domain (Table 4).Discussion
The purpose of this study was to finalize content, structure, and
scoring of the FLU-PRO and assess the performance properties of
this new instrument in adults with laboratory-confirmed influ-
enza [10]. A reliable and accurate measurement tool providing a
comprehensive profile of influenza symptoms on the basis of
concepts that patients have stated are relevant will facilitate
conduct of population-level epidemiologic studies, natural his-
tory studies, and clinical trials.ay 14. FLU-PRO, inFLUenza Patient-Reported Outcome.
Table 3 – Known-groups validity: 32-item FLU-PRO scores by Patient Global Rating of Disease Severity, day 1.





symptoms (n ¼ 50)
Moderate
symptoms (n ¼ 77)
Severe/very severe
symptoms (n ¼ 94)
Nose 1.29  0.88 1.56  0.95 2.01  1.15 8.9† 2†, 3‡
Throat 0.85  0.83 1.24  1.03 1.73  1.24 11.4† 2†, 3‡
Eyes 0.51  0.88 0.82  0.98 1.37  1.19 12.3† 2†, 3§
Chest/respiratory 1.37  0.69 1.75  0.86 2.20  0.86 17.5† 1‡, 2†, 3§
Gastrointestinal 0.29  0.43 0.48  0.65 1.06  1.00 19.8† 2†, 3†
Body/systemic 1.03  0.64 1.60  0.78 2.48  0.77 67.5† 1†, 2†, 3†
Total score 0.98  0.47 1.38  0.57 2.01  0.63 57.2† 1†, 2†, 3†
Notes. Higher FLU-PRO scores ¼ more severe symptoms.
FLU-PRO, inFLUenza Patient-Reported Outcome.
* Pairwise comparisons between means will be performed using Scheffe test adjusting for multiple comparisons: 1 ¼ No/mild symptoms vs.
Moderate; 2 ¼ No/mild symptoms vs. Severe and Very severe; and 3 ¼ Moderate symptoms vs. Severe and Very severe.
† P o 0.001.
‡ P o 0.05.
§ P o 0.01.A 37-item draft measure was developed on the basis of patient
descriptions of influenza and included content-redundant items
for evaluation and elimination during quantitative analysis [13].
Five redundant and lower performing items were removed on the
basis of qualitative and quantitative information to yield the final
32-item questionnaire. Patients participating in cognitive inter-
views [13] found the 37-item questionnaire easy to complete with
uninterrupted response times of 5 minutes, suggesting that the
final instrument should perform similarly. The six-domain/sub-
scale structure of the FLU-PRO is clinically intuitive and consis-
tent with body systems commonly affected by influenza. The
mean-based scoring algorithm is easy to use and interpret, with
higher scores indicating more severe symptoms. Each body
system/domain is represented in the score profile, with the two
domains most important to patients and clinicians, chest/respi-
ratory and systemic symptoms, more heavily weighted in the
total score.
Results suggest that FLU-PRO scores are reliable, valid, and
responsive to improvements in health as patients recover from
influenza. Consistent with a priori hypotheses, scores were
significantly related to patient global ratings of influenza severity,
interference in daily activities, and physical health. Correlations
were similar or higher than those reported for the Influenza
Intensity and Impact Questionnaire (FluiiQ), in which day 1
Spearman correlations between FluiiQ total score and global
ratings of severity, the feeling thermometer, and health were
0.44, 0.27, and 0.23 [6]. For the FluiiQ respiratory domain,
correlations with the three criterion measures were 0.35, 0.15,
and 0.08; coefficients for the systemic domain were 0.41, 0.27,
and 0.24. The FLU-PRO data supported known-groups validity
because scores were the lowest in patients rating No/mild
symptoms, higher in the Moderate group, and the highest in
the Severe/very severe group. Finally, the FLU-PRO demonstrated
responsiveness to change from day 1 to day 7, with responders
defined by reports of return to usual health and activities.
The purpose of this study was to perform empirically based
item reduction, test the factor structure of the measure, develop a
scoring algorithm, and evaluate the instrument for reliability and
responsiveness associated with recovery. Global ratings were
used in the responsiveness analyses, similar to the approach
used by others to estimate cross-sectional validity [6]. We did not
ask patients to record response to the FluiiQ because we used the
same validation method as that instrument, and asking illpatients with influenza to complete 61 questions daily (37-item
FLU-PRO pool and 24-item FluiiQ) would have been burdensome,
potentially causing missing data and larger dropout rates. FLU-
PRO may be more comprehensive, because FluiiQ assesses two
domains, respiratory and systemic, whereas the FLU-PRO
assesses six body systems. The systemic subscales of the two
instruments include some common content, with 4 of the FLU-
PRO’s 11 systemic symptoms (α ¼ 0.87) also represented in the
FluiiQ’s seven-item systemic scale (α ¼ 0.85) [6], suggesting that
these subscales may have high correlation. The respiratory scales
of the two measures are, however, different. FluiiQ respiratory
domain includes three items (cough, sore throat, and nasal
congestion) (α ¼ 0.48) [6]. The FLU-PRO yields separate scores
for nose (α ¼ 0.81), throat (α ¼ 0.81), and chest/respiratory (α ¼
0.80), with the latter assessing trouble breathing, chest conges-
tion, chest tightness, and four questions related to cough and
mucus. The content and internal consistency estimates suggest
that the FLU-PRO chest/respiratory domain provides a more
precise picture of the respiratory symptoms of influenza than
does the FluiiQ.
The present study had several limitations. Hospitalized
patients were included in the validation patient population, but
specific details about hospitalization (e.g., duration of influenza
before hospitalization, acuity level during hospitalization, and
concurrent complicating conditions) are unknown. Results sug-
gest that the FLU-PRO performs consistently in hospitalized and
clinic-based samples; nevertheless, additional study in both
groups is warranted. Missing data increased over time with
geographic variance in the rate of missing data. This may be
due, in part, to the interviewer-administered methods used in
several ex-US sites. The high rate of compliance through symp-
tom resolution suggests that the most relevant days of influenza
episodes were captured and missing data were not informative.
One of the strengths of the study is international participation
but this necessitated several modes of administration to meet
local data collection needs and preferences. Because mode was
nested under country (e.g., interviewer-administered question-
naires in Mexico and self-administration in the United States),
effects for mode and country could not be factored out and
tested. Finally, because this was a naturalistic study to validate
the instrument and not a randomized trial to determine treat-
ment effects of interventions, the relationship between symptom
severity and medication use is indeterminate; that is, subjects
Table 4 – Responsiveness of 32-item FLU-PRO by patient return to usual health (N ¼ 147)* or return to usual
activities (N ¼ 126)†, day 1–day 7.












LS mean  SD
Nose
Usual health 1.7  1.1 0.4  0.5 1.3  0.1 1.6  1.1 0.8  0.7 0.8  0.1 o0.0001
Usual
activities
1.8  1.0 0.6  0.6 1.1  0.1 1.3  1.2 0.7  1.0 0.8  0.1 0.0375
Throat
Usual health 1.1  1.0 0.1  0.3 1.2  0.1 1.5  1.2 0.5  0.7 0.9  0.1 0.0010
Usual
activities
1.4  1.1 0.3  0.5 1.1  0.1 1.6  1.3 0.6  0.9 0.8  0.1 0.0244
Eyes
Usual health 1.0  1.0 0.1  0.4 0.9  0.1 1.1  1.2 0.4  0.7 0.7  0.1 0.0452
Usual
activities
1.0  1.1 0.2  0.6 0.9  0.1 1.3  1.3 0.5  0.8 0.7  0.1 0.1166
Chest/
respiratory
Usual health 1.4  0.8 0.5  0.6 1.1  0.1 2.0  0.8 1.2  0.7) 0.7  0.1 o0.0001
Usual
activities
1.8  0.8 0.8  0.7 1.0  0.1 2.0  0.9 1.4  0.8 0.6  0.1 0.0003
Gastrointestinal
Usual health 0.5  0.8 0.1  0.5 0.5  0.1 0.7  0.8 0.3  0.4 0.4  0.0 0.2062
Usual
activities
0.7  0.8 0.2  0.4 0.5  0.0 0.6  0.9 0.4  0.5 0.3  0.1 0.0169
Body/systemic
Usual health 1.6  0.9 0.2  0.5 1.5  0.1 1.9  1.0 0.6  0.6 1.2  0.1 0.0004
Usual
activities
1.9  0.9 0.4  0.5 1.5  0.1 1.9  1.0 0.9  0.8 1.0  0.1 o0.0001
Total score
Usual health 1.3  0.6 0.3  0.4 1.2  0.1 1.6  0.8 0.7  0.5 0.8  0.0 o0.0001
Usual
activities
1.6  0.7 0.5  0.4 1.1  0.0 1.6  0.8 0.8  0.6 0.7  0.1 o0.0001
FLU-PRO, inFLUenza Patient-Reported Outcome; LS, least squares.
* Responders: N ¼ 51; nonresponders: N ¼ 96.
† Responders: N ¼ 87; nonresponders: N ¼ 39.
‡ Responders are defined as patients responding that they have returned to their usual health or usual activities at day 7.using one or more drugs could have more or fewer symptoms.
This would, however, not affect evaluation of the instrument
itself. Differences in symptom occurrence and severity between
influenza and ILI are not definitely known. Thus, neither variable
could be used to test known-groups validity. Future articles will
describe the use of the FLU-PRO in patients who test negative for
influenza. Further use and testing of the FLU-PRO in randomized
controlled trials, varied treatment settings, and epidemiologic
studies is warranted.
The content validity of the FLU-PRO has been established in
children and adolescents through qualitative research [13]. Quan-
titative testing in this population is warranted. Future research
using the FLU-PRO in influenza challenge studies will provide
data on the full course of influenza, from the pre-influenza
asymptomatic state to symptom resolution. The FLU-PRO is also
being evaluated for use in disease due to other acute respiratory
viruses.Conclusions
This study used quantitative methods to develop and test the
FLU-PRO for evaluating patient-reported symptoms in patients
with influenza. This new instrument yields a profile of scoresacross six body systems with a total score reflecting overall
symptom severity. Results suggest that FLU-PRO scores are
reliable, valid, and responsive to change in adults with
laboratory-confirmed influenza. The profile can be used to under-
stand and compare symptomatic manifestations of various
influenza strains, dominant systems across settings or patient
subgroups, and patterns of change over time, including differ-
ential symptom onset and recovery patterns. The instrument is
available for further testing and use as a standardized method for
evaluating symptoms of influenza in natural history studies and
clinical trials.Acknowledgments
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